{
  "slug": "eris-biotech",
  "name": "Eris Biotech",
  "yc_id": 29470,
  "batch": "Winter 2024",
  "website": "http://www.erisbio.com",
  "web_data": {
    "web_enrichment_version": "1.0.0",
    "enriched_at": "2025-10-17T01:29:55.889373",
    "website": "http://www.erisbio.com",
    "website_status": {
      "reachable": true,
      "status_code": 200,
      "response_time_ms": 2422.2,
      "final_url": "http://www.erisbio.com/",
      "redirected": true,
      "checked_at": "2025-10-17T01:29:58.311583"
    },
    "ssl_security": {
      "disabled": true,
      "reason": "certificate_verification_failed"
    },
    "domain_info": {
      "domain": "erisbio.com",
      "registrar": "Cloudflare, Inc.",
      "creation_date": "2023-05-20T19:16:26",
      "expiration_date": "2026-05-20T19:16:26",
      "domain_age_days": 880,
      "domain_age_years": 2.4,
      "name_servers": [
        "NANCY.NS.CLOUDFLARE.COM",
        "WALT.NS.CLOUDFLARE.COM"
      ]
    },
    "social_links": {
      "twitter": null,
      "linkedin": "https://www.linkedin.com/company/eris-biotech",
      "github": null,
      "facebook": null,
      "instagram": null,
      "youtube": null
    },
    "security_headers": {
      "strict_transport_security": false,
      "content_security_policy": false,
      "x_frame_options": true,
      "x_content_type_options": true,
      "x_xss_protection": false,
      "referrer_policy": false,
      "security_score": 33,
      "server": "Squarespace"
    }
  },
  "enrichment_version": "1.0.0",
  "enriched_at": "2025-10-17T10:41:30.553659",
  "phase1_complete": true,
  "phase2_complete": false,
  "phase3_complete": false,
  "phase4_complete": false,
  "phase5_complete": false,
  "ai_insights": {
    "ai_insights_version": "1.0.0-claude",
    "model_used": "claude-sonnet-4-20250514",
    "enriched_at": "2025-10-17T10:53:32.020915",
    "market_analysis": {
      "market_size": "very large",
      "market_stage": "growing",
      "key_trends": [
        "Immunotherapy becoming standard of care",
        "Small molecule drug development gaining traction over biologics",
        "Precision oncology targeting specific tumor types"
      ]
    },
    "competitive_positioning": {
      "competitive_moat": "Proprietary small molecule approach to immune suppression inhibition",
      "differentiation": "Focus on small molecules vs biologics for immune system engagement",
      "competitive_advantages": [
        "Small molecule drugs typically easier to manufacture and administer",
        "Targeting underserved mesothelioma market initially"
      ],
      "competitive_vulnerabilities": [
        "Competing against established immunotherapy giants",
        "Small team size limits R&D capacity"
      ]
    },
    "business_model": {
      "revenue_model": "Pharmaceutical licensing/partnerships",
      "scalability": "high",
      "capital_intensity": "high"
    },
    "growth_assessment": {
      "growth_stage": "pre-seed",
      "growth_indicators": [
        "Y Combinator backing",
        "Established domain presence",
        "Clear therapeutic focus"
      ],
      "growth_bottlenecks": [
        "Regulatory approval timelines",
        "Clinical trial funding requirements",
        "Small team capacity"
      ]
    },
    "risk_analysis": {
      "market_risk": "medium",
      "technology_risk": "high",
      "execution_risk": "high",
      "overall_risk_score": 8,
      "key_risks": [
        "Clinical trial failure",
        "Regulatory approval challenges",
        "Competition from Big Pharma"
      ]
    },
    "investment_thesis": {
      "strengths": [
        "Large addressable market",
        "Novel approach to immunotherapy",
        "Y Combinator validation"
      ],
      "concerns": [
        "Very early stage with high development risk",
        "Small team for complex biotech venture",
        "Long development timelines"
      ],
      "exit_potential": "acquisition",
      "comparable_companies": [
        "Kura Oncology",
        "Mirati Therapeutics"
      ]
    },
    "recommendations": {
      "next_steps": [
        "Expand team with experienced drug development talent",
        "Secure preclinical data for lead compounds"
      ],
      "expansion_opportunities": [
        "Partnership with larger pharma for development support",
        "Expand beyond mesothelioma to other solid tumors"
      ]
    },
    "tokens_used": {
      "input": 682,
      "output": 560,
      "total": 1242,
      "estimated_cost": 0.010446
    },
    "status": "success"
  },
  "phase8_complete": true
}